Jennifer L Taubert sold $10M of JNJ
EVP, WWC. Innovative Medicine at JOHNSON & JOHNSON. 56,471 shares at an average of $177.81, traded Sep 4, 2025, filed Sep 5, 2025.
Score components
- +15RoleOfficer
- +25Trade size$10.0M at market
- +5Share of holdings soldSold 24% of holdings
- +8Cluster2 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +5.7%, 3m +13.9%, 6m +36.3%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000200406-25-000186, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 4, 2025 | MOption exercise Common Stock | +56,471 | $101.87 | $5.8M | 234,484 | Sep 5, 2025 |
| Sep 4, 2025 | SOpen-market sale Common Stock | -56,471 | $177.81 | $10M | 178,013 | Sep 5, 2025 |
| Sep 4, 2025 | MOption exercise Employee Stock Options (Right to Buy)derivative | -56,471 | $101.87 | $5.8M | 0 | Sep 5, 2025 |
Related signals
Other insiders at JOHNSON & JOHNSON and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | JNJsell JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $9.2M 33,597 shares | -92% | |
| 40Moderate | JOHNSON & JOHNSON | Jennifer L Taubert EVP, WWC. Innovative Medicine | $4.0M 15,000 shares | -7% | |
| 60Notable | JOHNSON & JOHNSON | Joaquin Duato CEO and Chairman of the Board | $32M 123,291 shares | -31% | |
| 70Notable | JOHNSON & JOHNSON | Joaquin Duato CEO and Chairman of the Board | $13M 48,480 shares | -15% | |
| 50Moderate | JOHNSON & JOHNSON | Elizabeth Forminard EVP, Chief Legal Officer | $4.1M 15,918 shares | -48% | |
| 45Moderate | JNJsell JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $5.8M 23,054 shares | -50% | |
| 25Weak | JNJsell JOHNSON & JOHNSON | Kathryn E Wengel EVP, Chief TO and Risk Officer | $2.4M 10,000 shares | -8% | |
| 45Moderate | JOHNSON & JOHNSON | Robert J Decker VP Corporate Controller | $1.0M 4,075 shares | -15% | |
| 49Moderate | JOHNSON & JOHNSON | Timothy Schmid EVP, WW Chair, MedTech | $325k 1,322 shares | -5% | |
| 45Moderate | JOHNSON & JOHNSON | Vanessa Broadhurst EVP, Global Corp Affairs | $1.5M 6,197 shares | -21% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.